featured
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer — The Penelope-B Trial
J. Clin. Oncol 2021 Apr 01;[EPub Ahead of Print], S Loibl, F Marmé, M Martin, M Untch, H Bonnefoi, SB Kim, H Bear, N McCarthy, M Melé Olivé, K Gelmon, J García-Sáenz, CM Kelly, T Reimer, M Toi, HS Rugo, C Denkert, M Gnant, A Makris, M Koehler, C Huang-Bartelett, MJ Lechuga Frean, M Colleoni, G Werutsky, S Seiler, N Burchardi, V Nekljudova, G von MinckwitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.